Leukemia, Lymphocytic
Oncology·MeSH: Leukemia, Lymphocytic, Chronic, B-Cell
Prevalence
30.4 / 100K
Incidence
7.5 / 100K/yr
4 drugs in development·3 companies·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Venetoclax | Merck & Co., Inc. (MRK) |
Phase 1(2)
Phase 4(1)
| Drug | Company |
|---|---|
| Pirtobrutinib | ELI LILLY & Co (LLY) |
Compare drugs
Frequently asked questions
How many drugs are in development for Leukemia, Lymphocytic?
BioSniper tracks 4 drugs in development for Leukemia, Lymphocytic across 3 companies.
How many clinical trials target Leukemia, Lymphocytic?
There are 1 clinical trial targeting Leukemia, Lymphocytic tracked by BioSniper.
What is the prevalence of Leukemia, Lymphocytic?
The estimated prevalence of Leukemia, Lymphocytic is approximately 30.4 per 100,000 population.
Deep-dive into Leukemia, Lymphocytic
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis